Translational Neuroscience

, Volume 1, Issue 1, pp 43–48 | Cite as

CSF tau proteins in differential diagnosis of dementia

  • Marina Boban
  • Helena Šarac
  • Ninoslav Mimica
  • Mihovil Mladinov
  • Christine Süßmair
  • Nibal Ackl
  • Benedikt Bader
  • Miljenko Huzak
  • Adrian Danek
  • Patrick R. Hof
  • Goran Šimić
Research Article
  • 40 Downloads

Abstract

Alzheimer’s disease (AD) and frontotemporal lobar degeneration (FTLD) represent an important differential diagnostic problem in clinical practice. The identification for new biomarkers that would help establishing the diagnosis and primary cause of the dementia is therefore highly relevant. The aim of this study was to investigate the diagnostic accuracy of three potential CSF biomarkers, total tau protein (t-tau), tau protein phosphorylated at threonine 181 (p-tau181), and tau protein phosphorylated at serine 199 (p-tau199) in the differential diagnosis of AD and FTLD patients in relatively young age groups. The concentrations of the three CSF biomarkers were measured in 25 FTLD patients, 27 AD patients, and 25 non-demented (ND) subjects. The CSF concentrations of all three markers were significantly higher in AD than in FTLD cases (p < 0.001) or ND controls (p < 0.001). No difference was observed in FTLD compared to the ND group, except for p-tau181 (p = 0.028). When sensitivity was set at 85% or higher, specificity in differentiation between FTLD and AD patients reached 40% for t-tau, 37.5% for p-tau181 and 56% for p-tau199. Improvement of the diagnostic accuracy upon logistic regression analysis with t-tau and p-tau199 as independent variables showed that 22 out of 25 FTLD patients could be correctly classified. In conclusion, none of the markers per se fulfilled the criteria for the „ideal“ marker (sensitivity and specificity higher than 85%). However, combination of t-tau and p-tau199 classified correctly 88% of FTLD patients, thus largely satisfying practical requirements.

Keywords

Alzheimer’s disease Frontotemporal lobar degeneration Cerebrospinal fluid ELISA Phosphorylation Tau proteins 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Galton C.J., Patterson K., Xuereb J.H., Hodges J.R., Atypical and typical presentations of Alzheimer’s disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases, Brain, 2000, 3, 484–498CrossRefGoogle Scholar
  2. [2]
    McKhann G.M., Albert M.S., Grossman M., Miller B., Dickson D., Trojanowski J.Q., Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick’s Disease, Arch. Neurol., 2001, 58, 1803–1809CrossRefPubMedGoogle Scholar
  3. [3]
    Zhukareva V., Vogelsberg-Ragaglia V., Van Deerlin V.M., Bruce J., Shuck T., Grossman M., et al., Loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementia, Ann. Neurol., 2001, 49, 165–175CrossRefPubMedGoogle Scholar
  4. [4]
    Zhukareva V., Sundarraj S., Mann D., Sjögren M., Blenow K., Clark C.M., et al., Selective reduction of soluble tau proteins in sporadic and familial frontotemporal dementias: an international follow-up study. Acta Neuropathol., 2003, 105, 469–476PubMedGoogle Scholar
  5. [5]
    Itoh N., Arai H., Urakami K., Ishiguro K., Ohno H., Hampel H., et al., Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer’s disease, Ann. Neurol., 2001, 50, 150–156CrossRefPubMedGoogle Scholar
  6. [6]
    Pijnenburg Y.A., Schoonenboom N.S., Rosso S.M., Mulder C., Van Kamp G.J., Van Swieten J.C., et al., CSF tau and Abeta42 are not useful in the diagnosis of frontotemporal lobar degeneration, Neurology, 2004, 62, 1649PubMedGoogle Scholar
  7. [7]
    Schoonenboom N.S., Pijnenburg Y.A., Mulder C., Rosso S.M., Van Elk E.J., Van Kamp G.J., et al., Amyloid β (1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease, Neurology, 2004, 62, 1580–1584PubMedGoogle Scholar
  8. [8]
    De Jong D., Jansen R.W., Pijnenburg Y.A., van Geel W.J., Borm G.F., Kremer H.P., et al., CSF neurofilament proteins in the differential diagnosis of dementia, J. Neurol. Neurosurg. Psychiatry, 2007, 78, 936–938CrossRefPubMedGoogle Scholar
  9. [9]
    McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M., Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease, Neurology, 1984, 34, 939–944PubMedGoogle Scholar
  10. [10]
    Neary D., Snowden J.S., Gustafson L., Passant U., Stuss D., Black S., et al., Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria, Neurology 1998, 51, 1546–1554PubMedGoogle Scholar
  11. [11]
    Schonknecht P., Pantel J., Werle E., Hartmann T., Essig M., Baudendistel K., et al., Cerebrospinal fluid protein tau levels in the differential diagnosis of Alzheimer’s disease, Fortschr. Neurol. Psychiatr., 2000, 68, 439–446 (in German)CrossRefPubMedGoogle Scholar
  12. [12]
    The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and the National Institute on Aging Working Group, Consensus report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”, Neurobiol. Aging, 1998, 19, 109–116CrossRefGoogle Scholar
  13. [13]
    Pijnenburg Y.A., Janssen J.C., Schoonenboom N.S., Petzold A., Mulder C., Stigbrand T., et al., CSF neurofilaments in frontotemporal dementia compared with early onset Alzheimer’s disease and controls. Dement. Geriatr. Cogn. Disord., 2007, 23, 225–230CrossRefPubMedGoogle Scholar
  14. [14]
    Forman M.S., Zhukareva V., Bergeron C., Chin S.S., Grossman M., Clark C., et al., Signature tau neuropathology in gray and white matter of corticobasal degeneration, Am. J. Pathol., 2002, 160, 2045–2053PubMedGoogle Scholar
  15. [15]
    Tumani H., Nau R., Felgenhauer K., Beta-trace protein in cerebrospinal fluid: a blood-CSF barrier-related evaluation in neurological diseases, Ann. Neurol. 1998, 44, 882–889CrossRefPubMedGoogle Scholar
  16. [16]
    Reiber H., CSF flow — its influence on CSF concentration of brain-derived and blood-derived proteins. In: Teelken A., Korf J. (Eds.), Neurochemistry, Plenum Press, New York, 1997, 423–432Google Scholar
  17. [17]
    Tapiola T., Overmyer M., Lehtovirta M., Helisalmi S., Ramberg J., Alafuzoff I., et al., The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer’s disease, Neuroreport, 1997, 8, 3961–3963CrossRefPubMedGoogle Scholar
  18. [18]
    Riemenschneider M., Wagenpfeil S., Diehl J., Lautenschlager N., Theml T., Heldmann B., et al., Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration, Neurology, 2002, 58, 1622–1628PubMedGoogle Scholar
  19. [19]
    Fabre S.F., Forsell C., Viitanen M., Sjögren M, Wallin A, Blennow K., et al., Clinic-based cases with frontotemporal dementia show increased cerebrospinal fluid tau and high apolipoprotein E epsilon4 frequency, but no tau gene mutations, Exp. Neurol., 2001, 168, 413–418CrossRefPubMedGoogle Scholar
  20. [20]
    Rosso S.M., van Herpen E., Heutink P., Total tau is not increased in cerebrospinal fluid of frontotemporal dementia patients with P301L and G272V tau mutations, Neurobiol. Aging, 2002, 23, S379Google Scholar
  21. [21]
    Rosso S.M., van Herpen E., Pijnenburg Y.A., Schoonenboom N.S., Scheltens P., Heutink P., et al., Total tau and phosphorylated tau 181 levels in the cerebrospinal fluid of patients with frontotemporal dementia due to P301L and G272V tau mutations, Arch. Neurol. 2003, 60, 1209–1213CrossRefPubMedGoogle Scholar
  22. [22]
    Buée L., Bussière T., Buée-Scherrer V., Delacourte A., Hof P.R., Tau protein isoforms, phosphorylation and role in neurodegenerative disorders, Brain Res. Rev., 2000, 33, 95–130CrossRefPubMedGoogle Scholar
  23. [23]
    Kertesz A., McMonagle P., Blair M., Davidson W., Munoz D.G., The evolution and pathology of frontotemporal dementia, Brain, 2005, 128, 1996–2005CrossRefPubMedGoogle Scholar
  24. [24]
    Varma A.R., Snowden J.S., Lloyd J.J., Talbot P.R., Mann D.M., Neary D., Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer’s disease and frontotemporal dementia, J. Neurol. Neurosurg. Psychiatry, 1999, 66, 184–188CrossRefPubMedGoogle Scholar
  25. [25]
    Bürger K., Zinkowski R., Teipel S.J., Tapiola T., Arai H., Blennow K., et al., Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231, Arch. Neurol., 2002, 59, 1267–1272CrossRefGoogle Scholar
  26. [26]
    Hampel H., Teipel S.J., Total and phosphorylated tau proteins: evaluation as core bomarker candidates in frontotemporal dementia, Dement. Geriatr. Cogn. Disord., 2004, 17, 350–354CrossRefPubMedGoogle Scholar
  27. [27]
    Blennow K., Vanmechelen E., Hampel H., CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer’s disease. Mol. Neurobiol., 2001, 24, 87–97CrossRefPubMedGoogle Scholar
  28. [28]
    Grossman M., Farmer J., Leight S., Work M., Moore P., Van Deerlin V., et al., Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer’s disease, Ann. Neurol., 2005, 57, 721–729CrossRefPubMedGoogle Scholar
  29. [29]
    Bürger K., Zinkowski R., Teipel S.J., Arai H., DeBernardis J., Kerkman D., et al., Differentiation of geriatric major depression from Alzheimer’s disease with CSF tau protein phosphorylated at threonine 231, Am. J. Psychiatry, 2003, 160, 376–379CrossRefGoogle Scholar
  30. [30]
    Bian H., Van Swieten J.C., Leight S., Massimo L., Wood E., Forman M., et al., CSF biomarkers in frontotemporal lobar degeneration with known pathology, Neurology, 2008, 70, 1827–1835CrossRefPubMedGoogle Scholar
  31. [31]
    Augustinack J.C., Schneider A., Mandelkow E.M., Hyman B.T., Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer’s disease, Acta Neuropathol., 2002;103:26–35.CrossRefPubMedGoogle Scholar
  32. [32]
    Boban M., Grbić K., Mladinov M., Hof P.R., Süssmair C. Ackl N., et al., Cerebrospinal fluid markers in differential diagnosis of Alzheimer’s disease and vascular dementia, Coll. Antropol., 2008, 32, 31–36PubMedGoogle Scholar
  33. [33]
    Hampel H., Bürger K., Zinkowski R., Teipel S.J., Görnitz A., Andreasen N., et al., Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study, Arch. Gen. Psychiatry, 2004, 61, 95–102CrossRefPubMedGoogle Scholar
  34. [34]
    Matsuo E.S., Shin R.W., Billingsley M.L., Van deVoorde A., O’Connor M., Trojanowski J.Q., et al., Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer’s disease paired helical filament tau, Neuron, 1994, 13, 989–1002CrossRefPubMedGoogle Scholar

Copyright information

© © Versita Warsaw and Springer-Verlag Wien 2010

Authors and Affiliations

  • Marina Boban
    • 1
    • 2
  • Helena Šarac
    • 3
  • Ninoslav Mimica
    • 4
  • Mihovil Mladinov
    • 3
  • Christine Süßmair
    • 5
  • Nibal Ackl
    • 5
  • Benedikt Bader
    • 6
  • Miljenko Huzak
    • 7
  • Adrian Danek
    • 5
  • Patrick R. Hof
    • 8
  • Goran Šimić
    • 3
  1. 1.School of MedicineUniversity of ZagrebZagrebCroatia
  2. 2.Department of NeurologyUniversity Hospital Centre ZagrebZagrebCroatia
  3. 3.Department of NeuroscienceCroatian Institute for Brain ResearchZagrebCroatia
  4. 4.Psychiatric Hospital VrapčeUniversity Department of PsychiatryZagrebCroatia
  5. 5.Neurologische KlinikKlinikum der Universität MünchenMuenchenGermany
  6. 6.Zentrum für Neuropathologie und PrionforschungLudwig-Maximilians-UniversitätMünchenGermany
  7. 7.Department of MathematicsUniversity of ZagrebZagrebCroatia
  8. 8.Department of NeuroscienceMount Sinai School of MedicineNew YorkUSA

Personalised recommendations